Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1976 Dec;85(3):661–673.

Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.

R N Germain, R M Williams, B Benacerraf
PMCID: PMC2032668  PMID: 826167

Abstract

Tumor-specific cytolytic activity, as measured by the 51Cr release assay, has been demonstrated in the draining lymph node cells from DBA/2 mice bearing the syngeneic P815 mastocytoma or SL2 lymphoma. This lytic activity is mediated by cytolytic T lymphocytes (CTL), since cytotoxicity is eliminated by treatment of the effector cells with anti-Thy 1.2 (theta) serum plus complement but is enhanced or unaffected by anti-Thy 1.2 serum alone, antimouse immunoglobulin plus complement, normal or aggregated mouse immunoglobulin, or removal of adherent cells. The time course of the CTL response has been analyzed and is similar for both P815 and SL2, with a peak around Days 10 to 12 after tumor grafting. Detectable CTL activity then wanes despite continued antigenic stimulation from the growing tumor. The ability of the immunotherapeutic agent Corynebacterium parvum to augment such specific CTL responses is documented as one antitumor pathway by which this agent may act.

Full text

PDF
661

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brunner K. T., Mauel J., Rudolf H., Chapuis B. Studies of allograft immunity in mice. I. Induction, development and in vitro assay of cellular immunity. Immunology. 1970 Apr;18(4):501–515. [PMC free article] [PubMed] [Google Scholar]
  2. Cerottini J. C., Brunner K. T. Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol. 1974;18:67–132. doi: 10.1016/s0065-2776(08)60308-9. [DOI] [PubMed] [Google Scholar]
  3. Chia E., Festenstein H. Specific cytostatic effect of lymph node cells from normal and T cell-deficient mice on syngeneic tumor target cells in vitro and its specific abrogation by body fluids from syngeneic tumor-bearing mice. Eur J Immunol. 1973 Aug;3(8):483–487. doi: 10.1002/eji.1830030806. [DOI] [PubMed] [Google Scholar]
  4. DUNN T. B., POTTER M. A transplantable mast-cell neoplasm in the mouse. J Natl Cancer Inst. 1957 Apr;18(4):587–601. [PubMed] [Google Scholar]
  5. Djeu J. Y., Glaser M., Hirchner H., Huang K. Y., Herberman R. B. The effect of specific anti-rat thymocyte serum on cell-mediated tumor immunity and other lymphocyte functions. Cell Immunol. 1974 Apr;12(1):164–169. doi: 10.1016/0008-8749(74)90068-9. [DOI] [PubMed] [Google Scholar]
  6. Evans R., Alexander P. Role of macrophages in tumour immunity. I. Co-operation between macrophages and lymphoid cells in syngeneic tumour immunity. Immunology. 1972 Oct;23(4):615–626. [PMC free article] [PubMed] [Google Scholar]
  7. Evans R., Grant C. K., Cox H., Steele K., Alexander P. Thymus-derived lymphocytes produce an immunologically specific macrophage-arming factor. J Exp Med. 1972 Nov 1;136(5):1318–1322. doi: 10.1084/jem.136.5.1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Greenberg A. H., Hudson L., Shen L., Roitt I. M. Antibody-dependent cell-mediated cytotoxicity due to a "null" lymphoid cell. Nat New Biol. 1973 Mar 28;242(117):111–113. doi: 10.1038/newbio242111a0. [DOI] [PubMed] [Google Scholar]
  9. Halloran P., Schirrmacher V., Festenstein H. A new sensitive assay for antibody against cell surface antigens based on inhibition of cell-dependent antibody-mediated cytotoxicity. I. Specificity and sensitivity. J Exp Med. 1974 Nov 1;140(5):1348–1363. doi: 10.1084/jem.140.5.1348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hellström K. E., Hellström I. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol. 1974;18:209–277. doi: 10.1016/s0065-2776(08)60311-9. [DOI] [PubMed] [Google Scholar]
  11. Herberman R. B. Cell-mediated immunity to tumor cells. Adv Cancer Res. 1974;19(0):207–263. doi: 10.1016/s0065-230x(08)60055-x. [DOI] [PubMed] [Google Scholar]
  12. Herberman R. B., Nunn M. E., Lavrin D. H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975 Aug 15;16(2):216–229. doi: 10.1002/ijc.2910160204. [DOI] [PubMed] [Google Scholar]
  13. Kiessling R., Klein E., Pross H., Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol. 1975 Feb;5(2):117–121. doi: 10.1002/eji.1830050209. [DOI] [PubMed] [Google Scholar]
  14. Kirchner H., Chused T. M., Herberman R. B., Holden H. T., Lavrin D. H. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med. 1974 Jun 1;139(6):1473–1487. doi: 10.1084/jem.139.6.1473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lamon E. W. The immune response to virally determined tumor associated antigens. Biochim Biophys Acta. 1974 Sep 9;355(2):149–176. doi: 10.1016/0304-419x(74)90002-x. [DOI] [PubMed] [Google Scholar]
  16. Lamon E. W., Wigzel H., Klein E., Andersson B., Skurzak H. M. The lymphocyte response to primary Moloney sarcoma virus tumors in BALB-c mice. Definition of the active subpopulations at different times after infection. J Exp Med. 1973 Jun 1;137(6):1472–1493. doi: 10.1084/jem.137.6.1472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Leclerc J. C., Gomard E., Levy J. P. Cell-mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in murine sarcoma virus (MSV)-induced tumors and transplanted lymphomas. Int J Cancer. 1972 Nov;10(3):589–601. doi: 10.1002/ijc.2910100318. [DOI] [PubMed] [Google Scholar]
  18. Oren M. E., Herberman R. B., Canty T. G. Immune response to Gross virus-induced lymphoma. II. Kinetics of the cellular immune response. J Natl Cancer Inst. 1971 Mar;46(3):621–628. [PubMed] [Google Scholar]
  19. Perlmann P., Perlmann H., Wigzell H. Lymphocyte mediated cytotoxicity in vitro. Induction and inhibition by humoral antibody and nature of effector cells. Transplant Rev. 1972;13:91–114. doi: 10.1111/j.1600-065x.1972.tb00061.x. [DOI] [PubMed] [Google Scholar]
  20. Plata F., Gomard E., Leclerc J. C., Levy J. P. Comparative in vitro studies on effector cell diversity in the cellular immune response to murine sarcoma virus (MSV)-induced tumors in mice. J Immunol. 1974 Apr;112(4):1477–1487. [PubMed] [Google Scholar]
  21. Plata F., Gomard E., Leclerc J. C., Levy J. P. Further evidence for the involvement of thymus-processed lymphocytes in syngeneic tumor cell cytolysis. J Immunol. 1973 Sep;111(3):667–671. [PubMed] [Google Scholar]
  22. REIF A. E., ALLEN J. M. THE AKR THYMIC ANTIGEN AND ITS DISTRIBUTION IN LEUKEMIAS AND NERVOUS TISSUES. J Exp Med. 1964 Sep 1;120:413–433. doi: 10.1084/jem.120.3.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Röllinghoff M., Wagner H. In vitro induction of tumor specific immunity: requirements for T lymphocytes and tumor growth inhibition in vivo. Eur J Immunol. 1973 Aug;3(8):471–476. doi: 10.1002/eji.1830030804. [DOI] [PubMed] [Google Scholar]
  24. Scollard D. Cellular cytotoxicity assays detect different effector cell types in vitro. Transplantation. 1975 Jan;19(1):87–90. doi: 10.1097/00007890-197501000-00017. [DOI] [PubMed] [Google Scholar]
  25. Takasugi M., Klein E. A microassay for cell-mediated immunity. Transplantation. 1970 Mar;9(3):219–227. doi: 10.1097/00007890-197003000-00005. [DOI] [PubMed] [Google Scholar]
  26. Takei F., Levy J. G., Kilburn D. G. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice. J Immunol. 1976 Feb;116(2):288–293. [PubMed] [Google Scholar]
  27. Wagner H., Röllinghoff M., Nossal G. J. T-cell-mediated immune responses induced in vitro: a probe for allograft and tumor immunity. Transplant Rev. 1973;17(0):3–36. doi: 10.1111/j.1600-065x.1973.tb00122.x. [DOI] [PubMed] [Google Scholar]
  28. Williams R. M., Germain R. N., Benacerraf B. Specific and nonspecific antitumor immunity. I. Description of an in vitro assay based on inhibition of DNA synthesis in tumor cells. J Natl Cancer Inst. 1975 Mar;54(3):697–708. [PubMed] [Google Scholar]
  29. Wright P. W., Ortiz de Landazuri M., Herberman R. B. Immune response to Gross virus-induced lymphoma: comparison of two in vitro assays of cell-mediated immunity. J Natl Cancer Inst. 1973 Apr;50(4):947–954. doi: 10.1093/jnci/50.4.947. [DOI] [PubMed] [Google Scholar]
  30. Zarling J. M., Tevethia S. S. Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. II. Evidence for macrophage participation at the effector level of tumor cell rejection. J Natl Cancer Inst. 1973 Jan;50(1):149–157. doi: 10.1093/jnci/50.1.149. [DOI] [PubMed] [Google Scholar]
  31. Zbar B., Bernstein I. D., Bartlett G. L., Hanna M. G., Jr, Rapp H. J. Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst. 1972 Jul;49(1):119–130. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES